1. Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19. Issue 10 (October 2022) Authors: Kotanidis, Christos P; Xie, Cheng; Alexander, Donna; Rodrigues, Jonathan C L; Burnham, Katie; Mentzer, Alexander; O'Connor, Daniel; Knight, Julian; Siddique, Muhammad; Lockstone, Helen; Thomas, Sheena; Kotronias, Rafail; Oikonomou, Evangelos K; Badi, Ileana; Lyasheva, Maria; Shirodaria, Cheerag; ... Journal: Lancet Issue: Volume 4:Issue 10(2022) Page Start: e705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Low‐dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms. (16th September 2019) Authors: Francis, Sebastian; Thomas, Sally; Luben, Robert; Sousos, Nikolaos; Mead, Adam; Snowden, John A.; Zeidler, Martin P. Journal: British journal of haematology Issue: Volume 187:Number 3(2019) Page Start: e69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. (17th June 2014) Authors: Harrison, Claire N.; Butt, Nauman; Campbell, Peter; Conneally, Eibhlin; Drummond, Mark; Green, Anthony R.; Murrin, Richard; Radia, Deepti H.; Mead, Adam; Reilly, John T.; Cross, Nicholas C. P.; McMullin, Mary F. Journal: British journal of haematology Issue: Volume 167:Number 3(2014:Nov.) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Issue 5 (May 2017) Authors: Mesa, Ruben A; Vannucchi, Alessandro M; Mead, Adam; Egyed, Miklos; Szoke, Anita; Suvorov, Aleksandr; Jakucs, Janos; Perkins, Andrew; Prasad, Ritam; Mayer, Jiri; Demeter, Judit; Ganly, Peter; Singer, Jack W; Zhou, Huafeng; Dean, James P; te Boekhorst, Peter A; Nangalia, Jyoti; Kiladjian, Jean-Jacq... Journal: Lancet Issue: Volume 4:Issue 5(2017) Page Start: e225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Practical management of patients with myelofibrosis receiving ruxolitinib. Issue 5 (October 2013) Authors: Harrison, Claire; Mesa, Ruben; Ross, David; Mead, Adam; Keohane, Clodagh; Gotlib, Jason; Verstovsek, Srdan Journal: Expert review of hematology Issue: Volume 6:Issue 5(2013) Page Start: 511 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Issue 1 (December 2016) Authors: Psaila, Bethan; Barkas, Nikolaos; Iskander, Deena; Roy, Anindita; Anderson, Stacie; Ashley, Neil; Caputo, Valentina; Lichtenberg, Jens; Loaiza, Sandra; Bodine, David; Karadimitris, Anastasios; Mead, Adam; Roberts, Irene Journal: Genome biology Issue: Volume 17:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead. (November 2017) Authors: Mead, Adam Journal: Future oncology Issue: Volume 13:Number 27(2017) Page Start: 2401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The transformative journey of chronic myeloid leukemia. (28th August 2018) Authors: Neelakantan, Pratap; Mead, Adam Journal: International journal of hematologic oncology Issue: Volume 7:Number 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗